These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 30592253)

  • 1. Pharmacological Approaches Targeting Brain Cell Survival in the Context of Neurodegeneration and Potential Treatment Strategies.
    Aliev G
    Curr Neuropharmacol; 2019; 17(3):198-200. PubMed ID: 30592253
    [No Abstract]   [Full Text] [Related]  

  • 2. PPARs: a new target for neuroprotection.
    Bordet R; Gelé P; Duriez P; Fruchart JC
    J Neurol Neurosurg Psychiatry; 2006 Mar; 77(3):285-7. PubMed ID: 16484630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multitarget Therapeutics for Neurodegenerative Diseases.
    Gabr MT; Yahiaoui S
    Biomed Res Int; 2020; 2020():6532827. PubMed ID: 32695817
    [No Abstract]   [Full Text] [Related]  

  • 4. Pediatric use of tetracyclines: focus on neurodevelopmental effects.
    Inta I; Hoffmann GF; Bettendorf M
    Pediatr Res; 2017 Nov; 82(5):725-726. PubMed ID: 28700569
    [No Abstract]   [Full Text] [Related]  

  • 5. Molecular mechanisms of neurodegeneration and neuroprotection--experimental approaches and the diseased brain.
    Schliebs R
    Int J Dev Neurosci; 2004 Nov; 22(7):441-2. PubMed ID: 15465273
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of insulin resistance in the neurodegeneration.
    Stefanelli M; Martocchia A; De Marinis EA; Falaschi GM; Romano G; Rufo M; Falaschi P
    Recent Pat CNS Drug Discov; 2014 Apr; 9(1):54-63. PubMed ID: 24724584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New therapeutic strategies for treatment of neurodegenerative diseases.
    Kazantsev AG
    Curr Pharm Des; 2009; 15(34):3917-8. PubMed ID: 20044916
    [No Abstract]   [Full Text] [Related]  

  • 8. Ubiquitin proteasome system as a pharmacological target in neurodegeneration.
    Hol EM; Fischer DF; Ovaa H; Scheper W
    Expert Rev Neurother; 2006 Sep; 6(9):1337-47. PubMed ID: 17009921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In search of the Holy Grail for the treatment of neurodegenerative disorders: has a simple cation been overlooked?
    Chuang DM; Manji HK
    Biol Psychiatry; 2007 Jul; 62(1):4-6. PubMed ID: 17572175
    [No Abstract]   [Full Text] [Related]  

  • 10. Microtubule-Directed Therapeutic Strategy for Neurodegenerative Disorders: Starting From the Basis and Looking on the Emergences.
    Cappelletti G; Cartelli D; Christodoulou MS; Passarella D
    Curr Pharm Des; 2017; 23(5):784-808. PubMed ID: 27981911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using Caenorhabditis elegans models of neurodegenerative disease to identify neuroprotective strategies.
    Kraemer B; Schellenberg GD
    Int Rev Neurobiol; 2007; 77():219-46. PubMed ID: 17178476
    [No Abstract]   [Full Text] [Related]  

  • 12. Matter of life and death: the pharmacological approaches targeting apoptosis in brain diseases.
    Cavallucci V; D'Amelio M
    Curr Pharm Des; 2011; 17(3):215-29. PubMed ID: 21348825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanoparticles in the brain: a potential therapeutic system targeted to an early defect observed in many neurodegenerative diseases.
    Gunawardena S
    Pharm Res; 2013 Oct; 30(10):2459-74. PubMed ID: 23625095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotection by tetracyclines.
    Domercq M; Matute C
    Trends Pharmacol Sci; 2004 Dec; 25(12):609-12. PubMed ID: 15530637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural polyphenols against neurodegenerative disorders: potentials and pitfalls.
    Ebrahimi A; Schluesener H
    Ageing Res Rev; 2012 Apr; 11(2):329-45. PubMed ID: 22336470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Neurodegeneration and neuroprotection in multiple sclerosis].
    Davydovskaia MV; Boĭko AN; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(7 Suppl 2):44-52. PubMed ID: 19891348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythropoietin: a neuroprotective agent in cerebral hypoxia, neurodegeneration, and epilepsy.
    Merelli A; Czornyj L; Lazarowski A
    Curr Pharm Des; 2013; 19(38):6791-801. PubMed ID: 23530506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melatonin as a versatile molecule to design novel multitarget hybrids against neurodegeneration.
    Ramos E; Egea J; de Los Ríos C; Marco-Contelles J; Romero A
    Future Med Chem; 2017 May; 9(8):765-780. PubMed ID: 28498717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frontiers in Clinical Neuroscience: Neurodegeneration and Neuroprotection. Proceedings of a symposium in Abel Lajtha's honour. Budapest, Hungary, 24-25 October 2002.
    Adv Exp Med Biol; 2004; 541():v-vii, 1-195. PubMed ID: 15104110
    [No Abstract]   [Full Text] [Related]  

  • 20. [The concept of neuroprotective agents as a treatment modulator in the development of brain diseases].
    Bordet R; Lestage P; Onteniente B;
    Therapie; 2007; 62(6):463-72. PubMed ID: 18316011
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.